Actinium (ATNM) Director June Almenoff Receives 45,000 RSU/Option Awards

What Happened June Almenoff, a director of Actinium Pharmaceuticals (ATNM), received equity awards on 2026-09-02 totaling 45,000 shares: 18,000 restricted stock units (RSUs) and 27,000 derivative option-style awards. Both grants show an acquisition price of $0.00 on the Form 4 (i.e., no cash paid on grant). This is an equity compensation grant (award), not a market purchase or sale—common for directors as part of compensation.

Key Details

• Transaction date: 2026-09-02; Form 4 filed 2026-09-04 (timely filing).
• Prices reported: $0.00 per share for both grants (standard for RSU/option awards); reported total cash exchanged = $0.
• Shares reported: 18,000 RSUs + 27,000 derivative awards = 45,000 total granted.
• Shares owned after transaction: not disclosed in the provided summary of the filing.
• Footnotes from the filing:
  • F1: The 18,000 RSUs vest 1/3 on each anniversary over three years.
  • F2: The 27,000 derivative awards vest in 50 equal monthly tranches beginning on the grant date.
• No indication this was a sale, gift, or 10b5-1 plan transaction.

Context These grants are routine director compensation and do not represent an open-market purchase or sale. RSUs convert to stock only as they vest; the derivative awards vest monthly per the filing. Such awards are informative about compensation structure but do not, by themselves, indicate the director buying or selling shares in the market.